Trek Financial LLC Lowers Stake in Boston Scientific Corporation $BSX

Trek Financial LLC lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 92.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,174 shares of the medical equipment provider’s stock after selling 38,145 shares during the period. Trek Financial LLC’s holdings in Boston Scientific were worth $303,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of BSX. Egerton Capital UK LLP lifted its holdings in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after buying an additional 3,671,548 shares during the period. Jennison Associates LLC lifted its holdings in Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after buying an additional 2,823,744 shares during the period. Alphinity Investment Management Pty Ltd purchased a new stake in Boston Scientific during the fourth quarter worth $252,918,000. Marshall Wace LLP lifted its holdings in Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after buying an additional 2,301,383 shares during the period. Finally, Credit Agricole S A purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at $204,812,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $53.02 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock’s fifty day moving average price is $64.19 and its 200 day moving average price is $82.33. Boston Scientific Corporation has a 1 year low of $52.81 and a 1 year high of $109.50. The company has a market cap of $78.80 billion, a price-to-earnings ratio of 22.18, a PEG ratio of 0.99 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the prior year, the firm earned $0.75 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s Seismiq intravascular lithotripsy program reached a first-patient milestone in the ELEGANCE registry, a modest positive signal for its interventional cardiology pipeline. Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
• Positive Sentiment: Zacks highlighted continued cardiovascular growth, pointing to FARAPULSE and WATCHMAN momentum as key drivers of the company’s long-term growth story. Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
• Neutral Sentiment: Boston Scientific filed a shelf registration tied to an ESOP-related offering and shareholders approved governance changes, including eliminating supermajority voting provisions and adding limited officer exculpation. This may improve flexibility and align incentives, but it also signals share issuance potential. Is Boston Scientific (BSX) Quietly Recasting Its Ownership Structure To Sharpen Its Investment Story?
• Neutral Sentiment: Morningstar’s view that Boston Scientific is significantly undervalued after the recent share-price reset may attract value-oriented investors, but it does not remove near-term execution concerns. Boston Scientific (BSX) Valuation After Morningstar Downgrade And Significantly Undervalued Rating
• Negative Sentiment: Insiders sold about $1.2 million of shares, which can weigh on sentiment because it suggests some hesitation at current levels. Boston Scientific Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
• Negative Sentiment: The stock has underperformed competitors and recent commentary points to margin pressure and weaker estimates, helping explain why BSX is trading lower relative to peers. Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Barclays decreased their price objective on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a report on Thursday, April 23rd. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Robert W. Baird decreased their price objective on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a report on Thursday, April 23rd. Finally, Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.